Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.30 -0.9%	$0.32	$0.20 ▼ $1.48	$77.17M	2.86	1.76 million shs	1.11 million shs
CNTX Context Therapeutics	$0.80 -4.9%	$0.78	$0.55 ▼ $2.75	$71.58M	2.11	297,981 shs	81,329 shs
JSPR Jasper Therapeutics	$4.74 -9.4%	$4.74	$3.13 ▼ $26.84	$71.20M	2.74	288,109 shs	211,812 shs
MIRA MIRA Pharmaceuticals	$1.20 +2.6%	$1.02	$0.51 ▼ $5.01	$20.18M	1.93	2.16 million shs	650,226 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+5.88%	+9.24%	+17.28%	-47.08%	-74.56%
CNTX Context Therapeutics	-3.55%	-10.79%	+39.99%	-4.58%	-54.66%
JSPR Jasper Therapeutics	-3.33%	+8.96%	+37.27%	-17.25%	-78.67%
MIRA MIRA Pharmaceuticals	+0.86%	+13.59%	+40.22%	+3.54%	+59.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.3218 of 5 stars	4.3	5.0	3.3	0.8	0.0
CNTX Context Therapeutics	1.9986 of 5 stars	3.6	2.0	3.2	0.0	0.6
JSPR Jasper Therapeutics	2.3798 of 5 stars	3.5	2.0	3.1	1.7	0.6
MIRA MIRA Pharmaceuticals	2.7726 of 5 stars	3.7	5.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.67	Moderate Buy	$1.83	510.00% Upside
CNTX Context Therapeutics	3.13	Buy	$6.17	672.77% Upside
JSPR Jasper Therapeutics	3.00	Buy	$62.50	1,218.57% Upside
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	1,066.67% Upside

Current Analyst Ratings Breakdown

Latest MIRA, JSPR, CNTX, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/21/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/9/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50
3/21/2025	ADAP Adaptimmune Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$3.15 ➝ $1.40
3/21/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/21/2025	CNTX Context Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.43	N/A	N/A	$0.17 per share	1.76
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	5/13/2025 (Estimated)
CNTX Context Therapeutics	-$23.96M	-$0.49	N/A	N/A	N/A	N/A	-58.76%	-55.80%	5/14/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$4.86	N/A	N/A	N/A	N/A	-67.64%	-58.53%	5/13/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$11.98M	-$0.52	N/A	N/A	N/A	N/A	-337.44%	-280.58%	5/12/2025 (Estimated)

Latest MIRA, JSPR, CNTX, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.17	N/A	N/A	N/A	$6.55 million	N/A
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	N/A	N/A	N/A	N/A	N/A
5/12/2025	N/A	MIRA MIRA Pharmaceuticals	-$0.15	N/A	N/A	N/A	N/A	N/A
3/28/2025	Q4 2024	MIRA MIRA Pharmaceuticals	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million
3/20/2025	Q4 2024	CNTX Context Therapeutics	-$0.05	-$0.04	+$0.01	N/A	N/A	N/A
2/27/2025	Q4 2024	JSPR Jasper Therapeutics	-$1.27	-$1.62	-$0.35	-$1.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
CNTX Context Therapeutics	N/A	36.91	36.91
JSPR Jasper Therapeutics	N/A	7.61	7.61
MIRA MIRA Pharmaceuticals	N/A	6.11	6.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CNTX Context Therapeutics	14.03%
JSPR Jasper Therapeutics	79.85%
MIRA MIRA Pharmaceuticals	35.16%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
CNTX Context Therapeutics	3.04%
JSPR Jasper Therapeutics	2.70%
MIRA MIRA Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	257.23 million	224.05 million	Optionable
CNTX Context Therapeutics	7	89.70 million	72.72 million	Not Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable
MIRA MIRA Pharmaceuticals	2	16.81 million	15.46 million	Not Optionable

MIRA, JSPR, CNTX, and ADAP Headlines

Recent News About These Companies

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

May 6 at 8:00 AM | accessnewswire.com

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April

May 5 at 1:54 AM | americanbankingnews.com

Mira Pharmaceuticals reports in vitro drug release data for topical Ketamir-2

April 25, 2025 | markets.businessinsider.com

MIRA Pain Treatment Expands Market Size Potential

April 23, 2025 | msn.com

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

April 23, 2025 | accessnewswire.com

Pharmaceutical Stock Jumps After Key Trial Findings

April 17, 2025 | msn.com

Mira Pharmaceuticals announces results for Ketamir-2 in diabetic neuropathy

April 17, 2025 | markets.businessinsider.com

Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial

April 17, 2025 | msn.com

MIRA Continues Positive Testing Run

April 16, 2025 | msn.com

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

April 16, 2025 | finance.yahoo.com

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

April 16, 2025 | accessnewswire.com

Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2

April 2, 2025 | markets.businessinsider.com

MIRA Enrolls Patients Amid Rapid Progress

April 2, 2025 | msn.com

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

April 1, 2025 | accessnewswire.com

Mira Pharmaceuticals signs binding LOI to acquire SKNY Pharmaceuticals

March 25, 2025 | markets.businessinsider.com

MIRA Pharmaceuticals in binding LOI to acquire SKNY Pharmaceuticals

March 25, 2025 | markets.businessinsider.com

MIRA bids for SKNY

March 24, 2025 | thepharmaletter.com

Mira seeks to buy Skny for its preclinical obesity, smoking cessation asset

March 24, 2025 | fiercebiotech.com

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

March 24, 2025 | accessnewswire.com

Mira Pharmaceuticals expands Ketamir-2 development with topical treatment

March 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
By Thomas Hughes | April 25, 2025
View If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

MIRA, JSPR, CNTX, and ADAP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.30 0.00 (-0.89%)

Closing price 03:59 PM Eastern

Extended Trading

$0.31 +0.01 (+3.33%)

As of 07:57 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Context Therapeutics NASDAQ:CNTX

$0.80 -0.04 (-4.85%)

Closing price 03:58 PM Eastern

Extended Trading

$0.83 +0.03 (+3.88%)

As of 07:56 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Jasper Therapeutics NASDAQ:JSPR

$4.74 -0.49 (-9.37%)

Closing price 04:00 PM Eastern

Extended Trading

$4.82 +0.09 (+1.79%)

As of 07:59 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.20 +0.03 (+2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 +0.03 (+2.08%)

As of 07:58 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time